NanoViricides Advances NV-387 to Phase II for MPox Treatment

NanoViricides, Inc. announced the progression of its lead antiviral candidate, NV-387, into Phase II clinical trials targeting MPox. The company has identified MPox as the primary focus due to its strategic benefits, including ongoing epidemic conditions in Africa and cost-effective trial operations in the region.

This clinical endeavor is expected to position NV-387 favorably in line with the US Strategic National Stockpile requirements, given the recent inefficacies of existing treatments like tecovirimat and brincidofovir. The trial is set to begin with a site already established in the Democratic Republic of Congo. NanoViricides has engaged a Clinical Research Organization to facilitate the trial.

Phase II protocols are under completion, with NV-387 manufacturing primarily done at the company's facility. The significant need for effective antiviral treatments in the current climate reinforces the initiative.